{"id":"NCT01121666","sponsor":"Finox AG","briefTitle":"Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment","officialTitle":"A Phase III Assessor-blinded Randomized Parallel Group Multi-centre Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA Versus Gonal-f) in Women for Assisted Reproductive Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-12","completion":"2013-03","firstPosted":"2010-05-12","resultsPosted":"2016-04-15","lastUpdate":"2016-04-15"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Infertility"],"interventions":[{"type":"DRUG","name":"Follitropin alfa","otherNames":[]}],"arms":[{"label":"Gonal-f® (Follitropin alfa)","type":"ACTIVE_COMPARATOR"},{"label":"AFOLIA-150 (Follitropin alfa)","type":"EXPERIMENTAL"}],"summary":"Ther purpose of this study is to show equivalence between AFOLIA and Gonal-f® with regard to the number of oocytes retrieved in women for assisted reproductive treatment.","primaryOutcome":{"measure":"Number of Oocytes Retrieved (Per Protocol Population)","timeFrame":"34-36 hours after hCG administration and after maximum 16 days of r-hFSH treatment","effectByArm":[{"arm":"AFOLIA-150 (Follitropin Alfa)","deltaMin":10.8,"sd":5.11},{"arm":"Gonal-f® (Follitropin Alfa)","deltaMin":10.6,"sd":6.06}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":24},"locations":{"siteCount":16,"countries":["Austria","Denmark","Germany","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":249},"commonTop":["Injection site erythema","Headache","Injection site haematoma","Ovarian hyperstimulation syndrome","Injection site pain"]}}